↓ Skip to main content

American Association for Cancer Research

Article Metrics

Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

Overview of attention for article published in Cancer Prevention Research, November 2013
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#5 of 1,208)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
24 news outlets
blogs
4 blogs
policy
3 policy sources
twitter
358 tweeters
facebook
3 Facebook pages

Citations

dimensions_citation
151 Dimensions

Readers on

mendeley
119 Mendeley
Title
Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial
Published in
Cancer Prevention Research, November 2013
DOI 10.1158/1940-6207.capr-13-0203
Pubmed ID
Authors

Mahboobeh Safaeian, Carolina Porras, Yuanji Pan, Aimee Kreimer, John T. Schiller, Paula Gonzalez, Douglas R. Lowy, Sholom Wacholder, Mark Schiffman, Ana C. Rodriguez, Rolando Herrero, Troy Kemp, Gloriana Shelton, Wim Quint, Leen-Jan van Doorn, Allan Hildesheim, Ligia A. Pinto

Abstract

The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine efficacy against 12-month HPV16/18 persistent infection was similarly high among women who received one, two, or the recommended three doses of the bivalent HPV16/18 L1 virus-like particle (VLP) vaccine. Live-attenuated viral vaccines, but not simple-subunit vaccines, usually induce durable lifelong antibody responses after a single dose. It is unclear whether noninfectious VLP vaccines behave more like live-virus or simple-subunit vaccines in this regard. To explore the likelihood that efficacy will persist longer term, we investigated the magnitude and durability of antibodies to this vaccine by measuring HPV16- and HPV18-specific antibodies by VLP-ELISA using serum from enrollment, vaccination, and annual visits through four years in four vaccinated groups; one-dose (n = 78), two-doses separated by one month (n = 140), two doses separated by six months (n = 52), and three scheduled doses (n = 120, randomly selected). We also tested enrollment sera from n = 113 HPV16- or HPV18 L1-seropositive women prevaccination, presumably from natural infection. At four years, 100% of women in all groups remained HPV16/18 seropositive; both HPV16/18 geometric mean titers (GMT) among the extended two-dose group were non-inferior to the three-dose group, and ELISA titers were highly correlated with neutralization titers in all groups. Compared with the natural infection group, HPV16/18 GMTs were, respectively, at least 24 and 14 times higher among the two-dose and 9 and 5 times higher among one-dose vaccinees. Antibody levels following one-dose remained stable from month 6 through month 48. Results raise the possibility that even a single dose of HPV VLPs will induce long-term protection.

Twitter Demographics

The data shown below were collected from the profiles of 358 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 119 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Peru 1 <1%
Canada 1 <1%
Spain 1 <1%
United Kingdom 1 <1%
Unknown 113 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 16 13%
Researcher 16 13%
Student > Doctoral Student 14 12%
Student > Master 13 11%
Student > Bachelor 13 11%
Other 32 27%
Unknown 15 13%
Readers by discipline Count As %
Medicine and Dentistry 48 40%
Agricultural and Biological Sciences 16 13%
Biochemistry, Genetics and Molecular Biology 12 10%
Immunology and Microbiology 8 7%
Social Sciences 3 3%
Other 16 13%
Unknown 16 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 460. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 July 2021.
All research outputs
#33,911
of 18,438,151 outputs
Outputs from Cancer Prevention Research
#5
of 1,208 outputs
Outputs of similar age
#287
of 199,550 outputs
Outputs of similar age from Cancer Prevention Research
#2
of 22 outputs
Altmetric has tracked 18,438,151 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,208 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,550 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.